OXIDIL injection Ceftriaxone Sodium Injection Uses Side effects Dose Contraindication In Urdu

OXIDIL injection Ceftriaxone Sodium injection Uses Side effects Dose Contraindication In Urdu


OXIDIL injection Ceftriaxone Sodium Injection Uses Side effects Dose Contraindication In Urdu

OXIDIL injection Ceftriaxone Sodium Injection Uses Side effects Dose Contraindication In Urdu


Ceftriaxone sodium is semi synthetic 3rd generation cephalosporin antibiotic, with a high degree of stability to beta lactamases. Broad- spectrum activity, effectiveness and convenience of long action.


Lower respiratory tract infections Caused by streptococcus pneumoniae. Staphylococcus aureus, Haemphilus influenzae, parainfluenzae, klebsiella pneumoniae Escherichla coli,

Combination therapy
In severe, life-threatening infections, the combination of Ceftriaxone sodium with aminoglycosides is indicated without awaiting the results of sensitivity tests. Because of physical incompatibility the two drugs must be administered separately, not mixed in one syringe. Infections with Pseuddmonas aeruginosa may require concomitant treatment Special dosage instructions.


OXIDIL injection

Patients with Renal Impairment
In patients with impaired renal function, there is no need to reduce the dosage of Ceftriaxone provided liver function is intact. Only in cases of pre-terminal renal failure (creatinine clearance <10ml per minute) should the daily dosage be limited to 2g or less. In severe renal impairment accompanied by hepatic insufficiency, the plasma concentration of Ceftriaxone should be determined at regular intervals and dosage adjusted. In patients undergoing dialysis, no additional supplementary dosing is required following the dialysis. Serum concentrations should be monitored, however, to determine whether dosage adjustments are necessary, since the elimination rate in these patients may be reduced
Patients with Hepatic Impairment
In patients with liver damage, there is no need for the dosage to be reduced provided renal function is intact


These dosages do not require modification in elderly patients provided that renal and hepatic function is satisfactory

Neonates, infants, and children up to 12 years

The ‘following dosage schedules are recommended for once-daily administration: Neonates (up to 14 days)
A daily dose of 20-50mg/kg body weight, not to exceed 50mg/kg
Infants and children (15 days to 12 y ars)
Standard therapeutic dosage: 20-80rn /kg body weight once daily. For children with body weights of 50kg or more, the usual adult dosage should be used. Doses of 50mg/kg or over should be given by slow int avenous infusion over at least 30 minutes Acute, uncomplicated gonorrhea
A single dose of 250mg intramuscularly should be administered
Pen-operative prophylaxis

A single dose of .1-2g depending on the risk of infection of 30-90 minutes prior to surgery. In colorectal surgery, 2g should be given intramuscularly (dosages greater than 1g should be divided and injected at more than one site), or by slow intravenous infusion, in conjunction with a suitable agent against anaerobic bacteria

OXIDIL injection Ceftriaxone Sodium Injection

Use in special populations:


Oxidil Injection Ceftriaxone crosses the placental barrier. Safety in human pregnancy has not been established. Reproductive studies in animals have shown no evidence of embryotoxicity, fetotoxicity, teratogenicity or adverse effects on male or female fertility, birth or prenatal & postnatal development. In primates, ho embryotoxicity or teratogenecity has been observed

Nursing Mothers 

Low concentrations of Ceftriaxone are excreted in human milk. Caution should be
exercised when Ceftriaxone administered to a nursing woman

As directed by the physician


of antibioticscontraindica*ed in a patient with known allergy to the cephalosporin class

Ceftriaxone Sodium Injection WARNINGS AND PRECAUTIONS:

As with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough patient history is taken. Pseudomembrrhhnous colitis (swelling  of the large intestine) has been reported with nearly at antibacterial agents, including Ceftriaxone. Therefore it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration a antibacterial agents. Superinfections with non-susceptible micro-organisms may occur as with other antibacterial agents. Shadows, which have been mistakenfor gallstones have been detected on sonograms of the gallbladder usually following doses higher than the standard recommended cose  These shadows are, however precipitates a calcium-Ceftriaxone which disappear on completion or discontinuation of Ceftriaxone therapy. Rarely have these findings been associated with symptoms. In symptomatic cases, conservative non-surgical management is recommended.


The Ceftriaxone treatment in symptomatic cases should be at the discretion of the physician. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing solutions or products, even via different infusion lines. Calcium-containing solutions of products must not be administered within 48 hrs. of the last administration of Ceftriaxone. Cases of fatal reactions with calcium-Ceftriaxone precipitates in lung and kidneys it neonates and premature has been described. In some cases the infusion lines an administration of Ceftriaxone and calcium-containing solutions differed. Cases of pancreatitis possibly of biliary obstruction etiology have been rarely reported in patients treated with Ceftriaxone.

Risk factors:

Most patients presented with risk factors for biliary stasis and biliary sludge e.g. preceding major therapy, severe illness, and total parenteral nutrition. A trigger or cofactor role of Ceftriaxone related biliary precipitation can not be ruled out Safety and effectiveness of Ceftriaxone in neonates, infants and children have been established for the dosages described under dosage and administration.

Studies have shown that Ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin. Therefore caution should be exercised when considering Ceftriaxone treatment in hyperbilirubinemia neonates. Ceftriaxone should not be used in neonates (especially premature) at risk of developing bilirubin encephalopathy. During prolonged treatment, the blood should be checked at regular intervals

As with other cephalosporins, anaphylactic reactions with fatal outcome have been 

reported, even if a patient is not KNOWn to be allergic or previously exposes

Ceftriaxone Sodium Injection ADVERSE EFFECTS:

Ceftriaxone is generally well tolerated; the most common adverse reactions associated
with Ceftriaxone are changing in white blood cell counts, local reactions at the site of administration, rash, and diarrhea. Like all medicines, this medicine can cause side-effects, although not everybody gets them. The following side-effects may happen with Ceftriaxone:

Incidence of adverse effects greater than 1%:

  • Eosinophilia (6%) 
  • Thrombocytosis (5.1%) high level of platelets count
  • Elevations in liver enzymes (3.1 – 3.3%)
  • Diarrhea (2.7%) loss motion
  • Leukopenia (2.1%)
  • Elevation in BUN (1.2%)
  • Local reactions–pain, tenderness, irritation (1%)
  • Rash (1.7%)

Less adverse effects

Some less frequently reported adverse events (Incidence < 1%) include phlebitis, itchiness, fever, chills, nausea, vomiting, elevations of bilirubin, elevations in creatinine, headache and dizziness. Ceftriaxone may precipitate in bile, causing biliary sludge, biliary pseudolithiasis, and gallstones, especially in children. Hypoprothrombinaemia and bleeding are specific side effects. Haemolysis is reported. It has also been reported to cause post-renal failure in children. Like other antibiotics, Ceftriaxone use can result in Clostridium difficile-associated diarrhea ranging from mild diarrhea to fatal colitis

Severe allergic reactions (Not known, the frequency cannot be estimated from the available data)

The signs may include:

  • Sudden swelling of the face, throat, lips °mouth. This can make it difficult to breathe or swallow
  • Sudden swelling of the hands, feet, and ankles
  • Severe skin rashes 
  • Exanthema
  • Allergic dermatitis
  • Urticaria,
  • Acute generalized exanthematous pustulosis (AGEP)
  • Severe cutaneous adverse reactions (Erythema multiforme, Stevens-Johnson syndrome or Lyell’s syndrome/toxic epidermal necrolysis)

Ceftriaxone Sodium Injection OVERDOSAGE In Urdu:

Therefore In overdosage Case, drug concentration would not be reduced by hemodialysis or peritciheal dialysis. There is no specific antidote. Treatment of overdosage should be symptomatic 

اکسیڈل انجکشن میں سیفٹریکزن پائی جاتی ہے جومختلف ڈوز میں آتی ہے
جو 250 500،1000،2000ملی گرام میں بنائی گئی ہے

اس کو ہم کن کن بیماریوں میں استعمال کرتے ہیں

گردن توڑ بخار
میعادی بخار
سانس کی نالی کی انفیکشن
پیشاب کی نالی کی انفیکشن
سینے کی انفیکشن

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.